Recorded revenues of $2.3 M and a net loss of $3.2 M in Q4/12 and for FY12, recorded revenues of $8.7 M and a net loss of $14.7 M. ATHX’s Q4 EPS of -$0.07 beat by $0.03 … while revenue of $2.3 M beat by $0.6 M. ATHX is continuing their focus and resources on developing MultiStem to treat neurological conditions, inflammatory and immune disorders, and cardiovascular disease. PFE continues to advance the ongoing P2 clinical trial in inflammatory bowel disease. ATHX also initiated the 3rd and final cohort of a double-blind, placebo-controlled P2 clinical trial to evaluate the administration of MultiStem to patients who have suffered a moderate to moderately severe ischemic stroke following an independent safety monitoring committee review that found that MultiStem was safe and well tolerated in both high and low dosages in the initial patient treatment groups. In a significant extension of the treatment window currently required by standard of care, ATHX is treating patients 1 to 2 days after the stroke has occurred, which is believed to be a clinically practical time frame. In previously published work, ATHX have seen that the administration of a single dose of MultiStem in pre-clinical models even several days after a stroke resulted in significant and durable recovery. A “good cash” position of $25.5 M in cash but, the burn rate … should be increasing in FY13 based on … increased R&D and clinical development costs … ATHX closed -$0.01 or -0.64% to $1.55 on 172.2 share volume. ATHX shares have been trading up since the 3/1 session at $1.51, up 51% from the $1.00 … it was trading on 12/20. Although, the RegMed sector’s been slipping down and sideways. ATHX shares has appreciated recently on “speculative and unedited” SeekingAlpha posts. ATHX is UP in the after market $0.10 and $0.06 in the pre-market – +3.87%% to $1.61. A “Speculative BUY” ranking ATHX … as the positive tone of the conference call resonated …hopefully, validating
...and so if you have stated...for years...that you have interested parties to partner with and you don't actually sign any deals: are you a liar? Or is your science inconclusive, or worse yet, ineffective?
And wow, Athersys has spent million and millions of dollars and still can't sign a MEANINGFUL partner? Ya can't have your cake and eat it too there Gil, and your stock price is going to reflect that!